Latest news with #ANX005
Yahoo
09-04-2025
- Health
- Yahoo
Annexon's Investigational Drug Shows Rapid Recovery And Durable Benefit In Rare Neurological Disorder
Annexon, Inc. (NASDAQ:ANNX) on Tuesday presented data for its late-stage targeted therapy, tanruprubart (formerly ANX005), for Guillain-Barré Syndrome (GBS). GBS is a neuromuscular emergency affecting at least 150,000 people worldwide yearly. The rare autoimmune disease is characterized by rapidly progressing and severe weakness that can lead to complete paralysis, often requiring intensive care and mechanical ventilation. Tanruprubart is a first-in-kind monoclonal antibody designed to block C1q, the initiating molecule of the classical complement cascade. In the Phase 3 pivotal trial of 241 patients, tanruprubart met the primary endpoint with consistent outcomes and rapid, more complete functional recovery versus placebo across multiple time points and clinical efficacy measures. Also Read: The primary endpoint, GBS-Disability Scale (DS), showed that after a single infusion of tanruprubart at 30 mg/kg dose, patients had a statistically significant 2.4-fold higher likelihood of being in a better state of health than placebo at Week 8 (p=0.0058). Highlights from the oral presentation include: New efficacy findings consistently demonstrated rapid recovery and durable benefits of tanruprubart across muscle strength, mobility, and disability measures: At Week 1, treated patients rapidly gained motor function and were 14-fold more likely to perform the Timed Up and Go (TUG) test, a standardized measure of mobility, balance and lower limb capacity. At Week 1, treated patients rapidly gained motor ability and showed more than a 2-point improvement on the Overall Neuropathy Limitation Scale (ONLS), a tool used to assess limitations in everyday activities of the upper and lower limbs New efficacy findings at Week 26 also demonstrated that the benefit of tanruprubart was durable, with twice the number of treated patients having no limitations on the ONLS compared to placebo. Treatment with tanruprubart enabled patients to walk independently and be off ventilation (for those requiring it) approximately a month earlier. Patients treated with tanruprubart also spent approximately a week less time in intensive care Tanruprubart was well tolerated, with no new safety signals or off-target effects. Price Action: ANNX stock is down 5.52% at $1.45 at the last check on Wednesday. Read Next:Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? This article Annexon's Investigational Drug Shows Rapid Recovery And Durable Benefit In Rare Neurological Disorder originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Sign in to access your portfolio
Yahoo
08-04-2025
- Business
- Yahoo
Annexon Highlights Pivotal Data on First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) and Showcases New GBS Education Campaign at American Academy of Neurology (AAN) 2025 Annual Meeting
Oral Presentation Features Phase 3 Data Showing Rapid Recovery and Durable Benefit of Tanruprubart (formerly ANX005) on Clinically Meaningful Measures across Multiple Stages of GBS Disease Education Campaign for Healthcare Providers called Move GBS Forward™ ( Highlights Life-altering Impact of GBS BRISBANE, Calif., April 08, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today presented data for its late-stage targeted therapy for GBS and showcased new disease education activities at the AAN Annual Meeting taking place April 5–9, 2025, in San Diego, California. An oral presentation today during the 'Clinical Trials Plenary' session featured results of the tanruprubart (formerly ANX005) Phase 3 placebo-controlled trial reinforcing its rapid and durable clinical benefits for patients with GBS. A replay of the session is available to AAN registrants. GBS is a neuromuscular emergency that affects at least 150,000 people worldwide each year, with no FDA-approved therapies. The rare autoimmune disease is characterized by rapidly progressing and severe weakness that can lead to complete paralysis, often requiring intensive care and mechanical ventilation. Tanruprubart is a first-in-kind monoclonal antibody designed to block C1q, the initiating molecule of the classical complement cascade. With a single infusion, tanruprubart halts ongoing neuroinflammation and nerve damage in the acute phase of GBS to improve and expedite overall recovery. "After decades without any advancement in treatment or care, there is an urgent need for therapies that work quickly and effectively to treat GBS. Tanruprubart is an exciting and novel therapy that has shown a rapid and durable biological effect that shuts down neuroinflammation and nerve damage, potentially stopping the disease in its tracks,' said Jeff Allen, M.D., Professor of Neurology, University of Minnesota. 'The results of this Phase 3 placebo-controlled study, combined with a real-world study of GBS patients treated with standard therapies underscores the benefits of rapidly blocking neuroinflammation. Tanruprubart has the potential to help patients get better faster and ultimately reach a better state of health than with existing therapies or without treatment, while significantly reducing the burden of care." First Placebo-Controlled Phase 3 Trial for GBS Presented in AAN Oral Presentation In the Phase 3 pivotal trial of 241 patients, tanruprubart met the primary endpoint with consistent outcomes and rapid, more complete functional recovery versus placebo across multiple time points and clinical efficacy measures. The primary endpoint, GBS-Disability Scale (DS), showed that after a single infusion of tanruprubart at 30 mg/kg dose, patients had a statistically significant 2.4-fold higher likelihood of being in a better state of health than placebo at Week 8 (p=0.0058). Highlights from the oral presentation at AAN include: New efficacy findings consistently demonstrated rapid recovery and durable benefits of tanruprubart across muscle strength, mobility and disability measures: At Week 1, treated patients rapidly gained motor function and were 14-fold more likely to perform the Timed Up and Go (TUG) test, a standardized measure of mobility, balance and lower limb capacity At Week 1, treated patients rapidly gained motor ability and showed more than a 2-point improvement on the Overall Neuropathy Limitation Scale (ONLS), a tool used to assess limitations in everyday activities of the upper and lower limbs New efficacy findings at Week 26 also demonstrated that the benefit of tanruprubart was durable, with twice the number of treated patients having no limitations on the ONLS compared to placebo The new findings build upon previously reported Phase 3 trial results that showed an improvement in the primary endpoint of GBS-DS at Week 8, as well as that twice the number of patients treated with tanruprubart fully recovered to normal (GBS-DS = 0) at Week 26, compared to placebo Treatment with tanruprubart enabled patients to walk independently and be off ventilation (for those requiring it) approximately a month earlier Patients treated with tanruprubart also spent approximately a week less time in intensive care Tanruprubart was well tolerated, with no new safety signals or off-target effects Results of the Phase 3 trial are reinforced by a Real World Evidence (RWE) study that matched tanruprubart-treated patients from the pivotal Phase 3 study with a Western world patient population treated with current standards of care, intravenous immunoglobulin (IVIg) or plasma exchange (PE). In the RWE study, tanruprubart showed a rapid increase in muscle strength with more complete recovery over IVIg or PE, consistent with benefits shown in the Phase 3 trial. The RWE study is planned for presentation at upcoming conferences. Disease Education Campaign Aims to Move Understanding of GBS Forward Annexon also announced a new education campaign for healthcare professionals called Move GBS Forward™, which is designed to advance awareness and understanding of the sudden and long-term impact of GBS to encourage prompt diagnosis and care. Featuring the striking image of a patient frozen in ice with the header 'Guillain-Barré Syndrome can trap your patients for a lifetime,' the campaign draws attention to the life-altering physical and mental consequences of GBS. The campaign website address is 'As a rare disease, GBS is often misunderstood and misdiagnosed contributing to the trauma that patients suffer as they experience the severe weakness and acute paralysis caused by nerve damage,' said Lisa Butler, President and CEO at the GBS/CIDP Foundation International. 'This new education campaign reflects the patient experience and feelings of being trapped. It will help get GBS on the map for many more healthcare providers, so that the GBS community can take a step forward towards a future where patients may have a quicker recovery and better outcomes.' Additionally, Annexon supported a symposium at AAN titled 'Advancing GBS Care: Latest Insights into the role of classical complement pathway in GBS' where experts discussed the current state of patient care and need for new targeted treatments. About Guillain-Barré Syndrome GBS is a rare neuromuscular emergency resulting from an acute autoantibody and classical complement-mediated attack on peripheral nerves that generally occurs post-infection in otherwise healthy persons. It is an acute, rapidly progressive disease with a narrow timeframe for therapeutic intervention. GBS results in the hospitalization of more than 22,000 people annually in the U.S. and Europe. The peripheral nerve damage progresses rapidly, causing acute neuromuscular paralysis that can lead to significant morbidity, disability and mortality. Currently, there are no approved treatments for GBS in the United States. The long-term disease burden associated with GBS has led to a multi-billion-dollar annual economic cost to the U.S. healthcare system alone. More information about the impact of GBS is available at About Annexon Annexon Biosciences (Nasdaq: ANNX) is developing therapeutics that stop classical complement-driven neurodegeneration as first-in-kind treatments for millions of people living with serious neuroinflammatory diseases of the body, brain and eye. Our novel scientific approach focuses on C1q, the initiating molecule of classical complement's potent inflammatory pathway that when misdirected can lead to tissue damage and loss. By targeting C1q, our immunotherapies are designed to stop this neuroinflammatory cascade in disease before it starts. Our pipeline spans three diverse therapeutic areas – autoimmune, neurodegenerative and ophthalmic diseases – and includes targeted investigational drug candidates designed to address the unmet needs of over 8 million people worldwide. Annexon's mission is to deliver game-changing therapies to patients so that they can live their best lives. To learn more visit Forward Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by terminology such as 'aim,' 'anticipate,' 'assume,' 'contemplate,' 'continue,' 'could,' 'design,' 'due,' 'estimate,' 'expect,' 'goal,' 'intend,' 'may,' 'objective,' 'plan,' 'positioned,' 'potential,' 'predict,' 'seek,' 'should,' 'target,' 'will,' 'would' and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. All statements other than statements of historical facts contained in this press release are forward-looking statements. These forward-looking statements include, but are not limited to, statements about: the ability of ANX005 to block C1q activity within a single infusion; the potential therapeutic benefit of ANX005, if approved, compared to IVIg/plasma exchange or existing therapies; the planned presentation of RWE at upcoming conferences; the ability to translate the results of the RWE study to a broad population of GBS patients; the impacts of the new education campaign (Move GBS Forward™); the potential benefits from treatment with anti-C1q therapy; and continuing advancement of the company's portfolio. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, risks and uncertainties related to: the company's history of net operating losses; the company's ability to obtain necessary capital to fund its clinical programs; the early stages of clinical development of the company's product candidates; the effects of public health crises on the company's clinical programs and business operations; the company's ability to obtain regulatory approval of and successfully commercialize its product candidates; any undesirable side effects or other properties of the company's product candidates; the company's reliance on third-party suppliers and manufacturers; the outcomes of any future collaboration agreements; and the company's ability to adequately maintain intellectual property rights for its product candidates. These and other risks are described in greater detail under the section titled 'Risk Factors' contained in the company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q and the company's other filings with the SEC. Any forward-looking statements that the company makes in this press release are made pursuant to the Private Securities Litigation Reform Act of 1995, as amended, and speak only as of the date of this press release. Except as required by law, the company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. Investor Contact: Joyce AllaireLifeSci Advisorsjallaire@ Media Contact: Sheryl SeapyReal Chemistry949-903-4750sseapy@ in to access your portfolio
Yahoo
03-04-2025
- Business
- Yahoo
Annexon Highlights Leadership in Advancing Clinical Research and Education for Guillain-Barré Syndrome (GBS) at American Academy of Neurology (AAN) 2025 Annual Meeting
Oral Plenary Presentation on Tuesday, April 8 Features Phase 3 Data for ANX005, the First Potential Targeted Therapy for GBS, Showing Rapid and Durable Benefit Across Clinical Measures and Time Points Educational Symposium Focuses on Advancing GBS Care and Role of Classical Complement Pathway New Disease Education Campaign 'Move GBS Forward' Draws Attention to Life-altering Physical and Mental Impact of GBS BRISBANE, Calif., April 03, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today highlights the company's leadership in advancing clinical research and education for GBS at the AAN Annual Meeting taking place April 5–9, 2025, in San Diego, California. Highlighted activities at the conference include: An oral plenary session, part of the 'Clinical Trials Plenary' session, for the first placebo-controlled Phase 3 trial in GBS, 'A Phase 3 Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of ANX005 in Patients with Guillain-Barré Syndrome (GBS)'. Presenter: Jeff Allen, MD, Professor of Neurology at the University of Minnesota Program Number: PL5.006 Date/Time: Tuesday, April 8, 10:30-10:45 a.m. Pacific Time An educational symposium, 'Advancing GBS Care: Latest Insights into the role of classical complement pathway in GBS,' where experts will discuss the risks associated with GBS, current state of patient care and need for new targeted treatments. Presenters: Jeff Allen, MD, Professor of Neurology at the University of Minnesota; Avni Kapadia, MD, Assistant Professor of Neurology at Baylor College of Medicine; and Nick Silvestri, MD, FAAN, Professor of Neurology, Associate Dean at University of Buffalo Date/Time: Tuesday, April 8, 6:00-7:00 p.m. Pacific Time At AAN (Booth #2133), Annexon is launching a new disease education campaign for healthcare professionals called 'Move GBS Forward,' which is designed to advance awareness and understanding of the sudden and long-term impact of GBS so as to encourage prompt diagnosis and care. GBS is a neuromuscular emergency that affects at least 150,000 people worldwide each year, with no FDA-approved therapies. This rare autoimmune disease is characterized by rapidly progressing and severe weakness that can lead to complete paralysis, often requiring intensive care and mechanical ventilation. ANX005 is a first-in-kind monoclonal antibody designed to block C1q, the initiating molecule of the classical complement cascade, with a single infusion to halt ongoing neuroinflammation and nerve damage in the acute phase of GBS to improve and expedite overall recovery. About Annexon Annexon Biosciences (Nasdaq: ANNX) is developing therapeutics that stop classical complement-driven neurodegeneration as first-in-kind treatments for millions of people living with serious neuroinflammatory diseases of the body, brain and eye. Our novel scientific approach focuses on C1q, the initiating molecule of classical complement's potent inflammatory pathway that when misdirected can lead to tissue damage and loss. By targeting C1q, our immunotherapies are designed to stop this neuroinflammatory cascade in disease before it starts. Our pipeline spans three diverse therapeutic areas – autoimmune, neurodegenerative and ophthalmic diseases – and includes targeted investigational drug candidates designed to address the unmet needs of over 8 million people worldwide. Annexon's mission is to deliver game-changing therapies to patients so that they can live their best lives. To learn more visit Forward Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by terminology such as 'aim,' 'anticipate,' 'assume,' 'believe,' 'contemplate,' 'continue,' 'could,' 'design,' 'due,' 'estimate,' 'expect,' 'goal,' 'intend,' 'may,' 'objective,' 'plan,' 'positioned,' 'potential,' 'predict,' 'seek,' 'should,' 'target,' 'will,' 'would' and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. All statements other than statements of historical facts contained in this press release are forward-looking statements. These forward-looking statements include, but are not limited to, statements about: the ability of ANX005 to block C1q activity within a single infusion; the potential therapeutic benefit of ANX005; the potential benefits from treatment with anti-C1q therapy; and continuing advancement of the company's portfolio. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, risks and uncertainties related to: the company's history of net operating losses; the company's ability to obtain necessary capital to fund its clinical programs; the early stages of clinical development of the company's product candidates; the effects of public health crises on the company's clinical programs and business operations; the company's ability to obtain regulatory approval of and successfully commercialize its product candidates; any undesirable side effects or other properties of the company's product candidates; the company's reliance on third-party suppliers and manufacturers; the outcomes of any future collaboration agreements; and the company's ability to adequately maintain intellectual property rights for its product candidates. These and other risks are described in greater detail under the section titled 'Risk Factors' contained in the company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q and the company's other filings with the SEC. Any forward-looking statements that the company makes in this press release are made pursuant to the Private Securities Litigation Reform Act of 1995, as amended, and speak only as of the date of this press release. Except as required by law, the company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. Investor Contact: Joyce AllaireLifeSci Advisorsjallaire@ Media Contact: Sheryl SeapyReal Chemistry949-903-4750sseapy@
Yahoo
16-03-2025
- Business
- Yahoo
Wells Fargo Predicts Up to ~440% Rally for These 2 ‘Strong Buy' Stocks
Stocks surged on Friday, with the S&P 500 soaring 2.13% as investors welcomed a break from tariff-driven turmoil. The market rebounded from a turbulent week, fueled by easing fears of a government shutdown and renewed confidence in the U.S. economy. Fresh February data signaled that inflation was cooling in line with the Federal Reserve's targets, helping to calm concerns about economic strain. Easily identify stocks' risks and opportunities. Discover stocks' market position with detailed competitor analyses. Looking at the bigger picture, Wells Fargo's senior global market strategist Scott Wren sees plenty of reasons for optimism. 'Uncertainty surrounding the ultimate outcome and effects of tariff policies should not be extrapolated to suggest the economy will ultimately deteriorate into a recession. Growth in the second half of last year was robust so some slowdown to a more sustainable pace makes sense… We have long recommended that investors needed to exercise patience and wait for opportunities to buy equities on pullbacks. We see the current pullback as an opportunity,' Wren opined. Wren isn't the only bull at Wells Fargo. Biotech expert and analyst Derek Archila is setting his sights on two stocks poised for massive gains – one of which could soar by as much as ~440%. If that's not enticing enough, according to the TipRanks database, both stocks are also rated as Strong Buys by the analyst consensus. Let's dive into what's making these picks stand out. Annexon Biosciences (ANNX) Wells Fargo's first pick is Annexon, a late-stage biopharmaceutical research firm specializing in diseases driven by the immune system's complement pathway. Annexon's approach targets C1q, a molecule that initiates this pathway and triggers harmful inflammation. By blocking C1q at its source, the company aims to halt disease progression, offering patients the potential for better outcomes and improved quality of life. Annexon has three flagship drug candidate programs, with ANX005 being the most advanced. This first-in-class monoclonal antibody is designed to block C1q activity, with a primary focus on Guillain-Barré syndrome (GBS), a rare but severe autoimmune condition. In a pivotal Phase 3 trial, ANX005 demonstrated strong tolerability and delivered faster, more complete functional recovery than placebo. In addition, a Real-World Evidence study found that ANX005-treated patients had faster and greater improvements in muscle strength and disability compared to those receiving standard-of-care treatments like intravenous immunoglobulin (IVIg) or plasma exchange. With these results in hand, Annexon is preparing to submit a Biologics License Application (BLA) to the FDA, with a pre-BLA meeting expected in the first half of 2025. Annexon's second flagship drug candidate, ANX007, is designed to help protect vision in people with a severe form of age-related macular degeneration (AMD) called geographic atrophy (GA). In the Phase 2 ARCHER trial, ANX007 did not significantly slow the progression of GA lesions but suggested a potential, dose-dependent benefit in preserving vision. Based on this, Annexon is now focusing on the drug's ability to maintain visual function. Encouraged by positive FDA feedback, Annexon is now advancing to ARCHER II, a larger Phase 3 trial, with enrollment expected to wrap up in the second half of 2025 and results anticipated in late 2026. Lastly, Annexon is pushing forward with ANX1502, an oral small molecule inhibitor targeting the active form of C1s, an enzyme associated with C1q. This approach aims to prevent the immune system from mistakenly attacking red blood cells, a key issue in cold agglutinin disease (CAD). Annexon is currently conducting an open-label, single-arm proof-of-concept (POC) study to evaluate ANX1502 in CAD patients. The trial aims to generate a dataset from up to seven patients, with data expected by mid-2025. With a strong pipeline and key catalysts on the horizon, Wells Fargo analyst Derek Archila sees ANNX's $2.60 share price as an attractive entry point. 'We remain bullish on shares, as we believe the Street underappreciates ANNX's ANX005 program in GBS and its commercial opportunity,' Archila noted. 'The stock appears cheap given ANX005's positive Ph3 data in GBS, and in our view, there is a high likelihood its BLA is accepted and it receives BTD [Breakthrough Therapy Designation], neither is being factored into the stock. Further, we think a more robust dataset for ANX1502 should be de-risking, so it's prob worth the wait… With several catalysts coming in 2025, we think the risk/reward is skewed to the upside.' And just how much upside? Archila rates ANNX an Overweight (i.e., Buy), with a $14 price target – suggesting a substantial ~440% surge over the next year. (To watch Archila's track record, click here) Overall, ANNX currently enjoys Wall Street's unwavering support. A full house of 7 Buy ratings results in a Strong Buy consensus. With an average price target of $14.20, analysts expect shares to trade at a 446% premium over the next 12 months. (See ANNX stock forecast) AnaptysBio (ANAB) The next stock on Wells Fargo's radar is Anaptys Bio, a clinical-stage biopharmaceutical company focused on immune-modulating therapies for autoimmune and inflammatory diseases. The company is advancing a unique class of drug candidates designed to enhance treatment options, particularly in dermatology, gastroenterology, and rheumatology. Leading AnaptysBio's pipeline is rosnilimab, which is currently being evaluated for several conditions, including rheumatoid arthritis (RA) and ulcerative colitis (UC). The company recently delivered encouraging news from its Phase 2b trial for RA, reporting that the study met its primary endpoint at Week 12 and showed statistical significance across multiple key secondary measures. Investors won't have to wait too long for more insights – full clinical and translational data is set for release in Q2 2025. Meanwhile, the global Phase 2 trial for UC is actively enrolling patients, with top-line results expected in Q4 2025. The trial will enroll 132 patients in randomized blocks and will assess two subcutaneously administered dose levels against a placebo. Beyond its in-house programs, AnaptysBio benefits from lucrative partnerships. The company has out-licensed its Imsidolimab program, a treatment for generalized pustular psoriasis, to Vanda Pharmaceuticals, securing a $10 million upfront payment, an additional $5 million for existing drug supplies, and a 10% royalty on future global sales. Vanda is preparing regulatory submissions to both the FDA and EU ahead of a commercial launch. Another major partnership is with GSK for Jemperli, an oncology drug approved in 2023, which generated $190 million in sales in Q4 2024. AnaptysBio reported $43.1 million in collaboration revenue for the quarter and $91.3 million for the full year, with the majority stemming from Jemperli. Wells Fargo analyst Archila remains optimistic about AnaptysBio's robust pipeline and royalty-generating partnerships, reinforcing confidence in the company's long-term potential. 'We believe rosnilimab's positive data in RA suggests activity enough to de-risk a future Ph3 and also its upcoming Ph2b read out in UC expected in 4Q25… We increase our POS [probability of success] for both ros' RA and UC programs, and think the stock setup remains good in 2025 as: 1) 28wk data will likely be good in 2Q25 since it's in responders; 2) UC read out is now 4Q, and has a higher POS; 3) Jemperli royalties should offer a floor value and is getting no credit today,' Archila explained. Backing up this bullish outlook, Archila rates ANAB shares an Overweight (i.e., Buy) with a price target of $51, implying ~205% upside potential over the next 12 months. The broader analyst community shares this confidence, with 9 of the 11 recent analyst reviews rating the stock as a Buy and 2 as a Hold, resulting in a Strong Buy consensus. ANAB shares are currently trading at $16.73, with an average target price of $41.78, suggesting an upside of ~150% over the one-year horizon. (See ANAB stock forecast) To find good ideas for stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analyst. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment. Questions or Comments about the article? Write to editor@ Sign in to access your portfolio
